AI-designed Polio Vaccine

About Evaxion

Evaxion is a clinical-stage biotechnology company pioneering the use of artificial intelligence for vaccine discovery and development. Its core asset is the AI-Immunology™ platform, a suite of AI models designed to predict optimal vaccine targets for personalized cancer vaccines and next-generation infectious disease vaccines. The company has a pipeline of in-house assets ranging from preclinical to Phase 2 and is publicly traded on Nasdaq. Evaxion's approach aims to address significant unmet needs in oncology and antimicrobial resistance.

Therapeutic Areas